A group of scientists is researching the possibility of utilizing a set of compounds developed for cancer treatment as a novel oral therapy for treating Alzheimer’s disease. Up until now, the team had only tested and evaluated injected epothilone D, a brain-penetrant MT-stabilizer, in mice and AD patients. However, in spite of the fact…
News
An abnormal protein in the brain may play an important role in the onset of Alzheimer’s disease, a group of scientists at the Mayo Clinic discovered. Although they still haven’t figured out whether this protein, called TAR DNA binding protein of 43kDa (TDP-43), is a cause of Alzheimer’s disease…
Southampton Scientist Verifies Effectiveness of Arthritis Drug in Slowing Alzheimer’s Progression
A drug prescribed for the treatment of arthritis is able to slow the progression of Alzheimer’s, according a study performed by researchers at the University of Southampton in the United Kingdom. Etanercept was administrated to patients with mild to moderate disease, and within a six-month period, the scientists verified that the…
As a result of new research conducted at the Mayo Clinic, patients with Alzheimer’s may all commonly share a newly discovered protein called TDP-43 as a potential cause for their disease, in addition to the well-known amyloid and tau proteins. Dr. Keith Josephs at the Mayo Clinic was the lead expert…
Recent Posts
- FDA designation may speed new treatment for Alzheimer’s psychosis August 3, 2026
- Study reports Alzheimer’s treatment gains in long-term care July 6, 2026
- Awareness month event has new name: Do What You Love to End Alzheimer’s June 1, 2026
- FDA approves Auvelity to treat Alzheimer’s-related agitation May 4, 2026
- Daily Alzheimer’s pill slows brain shrinkage, boosts cognition April 6, 2026